5. GENDER EQUALITY

-$0.78 Earnings Per Share Expected for Myovant Sciences Ltd (NYSE:MYOV) This Quarter – MarketBeat

-$0.78 Earnings Per Share Expected for Myovant Sciences Ltd (NYSE:MYOV) This Quarter  MarketBeat

Wall Street brokerages expect Myovant Sciences Ltd (NYSE:MYOV) to post earnings per share of ($0.78) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Myovant Sciences’ earnings, with the lowest EPS estimate coming in at ($0.87) and the highest estimate coming in at ($0.71). Myovant Sciences posted earnings per share of ($0.79) in the same quarter last year, which would suggest a positive year over year growth rate of 1.3%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 10th.

According to Zacks, analysts expect that Myovant Sciences will report full year earnings of ($2.82) per share for the current financial year, with EPS estimates ranging from ($3.09) to ($2.55). For the next year, analysts anticipate that the firm will report earnings of ($2.82) per share, with EPS estimates ranging from ($3.52) to ($1.55). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31. The business had revenue of $33.33 million for the quarter.

Several research analysts have commented on the company. SVB Leerink cut their price target on Myovant Sciences from $29.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 12th. JPMorgan Chase & Co. lifted their target price on Myovant Sciences from $19.00 to $26.00 and gave the company an “overweight” rating in a research note on Monday, June 1st. ValuEngine upgraded Myovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 27th. Citigroup lifted their target price on Myovant Sciences from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, June 2nd. Finally, Evercore ISI lifted their target price on Myovant Sciences from $45.00 to $55.00 and gave the company a “positive” rating in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $27.36.

(Ad)

He’s found 40 1,000% or higher stock market winners. He beat 650 of the world’s most famous investors in a trading contest. And today, he’s revealing the critical top trend to watch and his next potential 1,000% winner for free, right here. No credit card, email address, or subscription required.

In related news, insider Ferreira Juan Camilo Arjona sold 2,058 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $20.01, for a total value of $41,180.58. Following the completion of the transaction, the insider now directly owns 138,026 shares in the company, valued at $2,761,900.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Matthew Lang sold 26,700 shares of the company’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $20.05, for a total value of $535,335.00. Following the completion of the transaction, the general counsel now owns 172,565 shares of the company’s stock, valued at $3,459,928.25. The disclosure for this sale can be found here. Insiders sold 57,658 shares of company stock valued at $1,155,066 over the last quarter. Insiders own 3.90% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. US Bancorp DE purchased a new stake in Myovant Sciences during the second quarter valued at about $41,000. PNC Financial Services Group Inc. boosted its position in shares of Myovant Sciences by 1,552.8% in the second quarter. PNC Financial Services Group Inc. now owns 2,661 shares of the company’s stock worth $55,000 after buying an additional 2,500 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Myovant Sciences by 28.6% in the first quarter. Tower Research Capital LLC TRC now owns 6,526 shares of the company’s stock worth $49,000 after buying an additional 1,453 shares during the period. Wells Fargo & Company MN boosted its position in shares of Myovant Sciences by 34.8% in the first quarter. Wells Fargo & Company MN now owns 8,530 shares of the company’s stock worth $64,000 after buying an additional 2,200 shares during the period. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Myovant Sciences in the second quarter worth about $200,000. 35.63% of the stock is owned by hedge funds and other institutional investors.

MYOV traded down $0.78 during trading on Wednesday, hitting $21.82. 958,336 shares of the stock were exchanged, compared to its average volume of 994,006. The firm has a market capitalization of $1.97 billion, a P/E ratio of -7.66 and a beta of 2.49. Myovant Sciences has a 1-year low of $4.14 and a 1-year high of $23.04. The stock has a fifty day moving average price of $19.15 and a two-hundred day moving average price of $14.89.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Story: Cryptocurrencies

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to

20 “Past Their Prime” Stocks to Dump From Your Portfolio

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster and others rise to the top of the markets. We’ve already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It’s hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won’t stay on the S&P 500 forever.

We’ve identified 20 companies that are past their prime. They aren’t at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

View the “20 “Past Their Prime” Stocks to Dump From Your Portfolio”.

Source: marketbeat.com

Leave a Comment